Navepegritide is under clinical development by Ascendis Pharma and currently in Phase III for Achondroplasia. According to GlobalData, Phase III drugs for Achondroplasia does not have sufficient historical data to build an indication benchmark PTSR for Phase III. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the Navepegritide LoA Report. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Navepegritide (TransCon CNP) is under development for the treatment of achondroplasia. It is administered through subcutaneous route. The drug candidate is a long-acting prodrug of the C-type natriuretic peptide conjugated to a multi-arm polyethene glycol carrier molecule through a cleavable linker. The drug candidate acts by targeting fibroblast-growth-factor-receptor 3 (FGFR3). It is developed based on the transcon technology.
Ascendis Pharma overview
Ascendis Pharma is a biopharmaceutical company that focuses on developing drugs for endocrinology and oncology indications. It is investigating TransCon hGH, a long-acting human growth hormone prodrug targeting GHD (growth hormone deficiency); TransCon PTH drug to treat hypoparathyroidism by restoring physiologic levels of PTH (parathyroid hormone); and TransCon CNP, a CNP (C-type natriuretic peptide) drug against achondroplasia (ACH). It is also evaluating TransCon TLR (toll-like receptor) 7/8 agonist, and TransCon IL-2 ß/?, an interleukin-2 variant that activates the IL-2 receptor beta/gamma (IL-2Rß/?) for the treatment of cancer. Ascendis Pharma utilizes its proprietary TransCon technology platform to develop its drugs. The company operates in the US, Germany and Denmark. Ascendis Pharma is headquartered in Hellerup, Denmark.
For a complete picture of Navepegritide’s drug-specific PTSR and LoA scores, buy the report here.